11/13
01:45 pm
olma
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Medium
Report
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
11/12
04:12 pm
olma
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/12
04:01 pm
olma
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/6
07:01 am
olma
Olema Oncology to Participate in Upcoming Investor Conferences
Medium
Report
Olema Oncology to Participate in Upcoming Investor Conferences
11/4
04:44 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/24
08:08 am
olma
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
10/23
07:00 am
olma
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
Medium
Report
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
10/9
07:00 am
olma
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Low
Report
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
10/2
04:30 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/4
04:55 pm
olma
Airbus, Rolls to brief airlines as pressure for A350 checks eases [Yahoo! Finance Canada]
Medium
Report
Airbus, Rolls to brief airlines as pressure for A350 checks eases [Yahoo! Finance Canada]
9/4
04:49 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)